These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23554297)

  • 21. Yellow fever vaccine: past, present and future.
    Roukens AH; Visser LG
    Expert Opin Biol Ther; 2008 Nov; 8(11):1787-95. PubMed ID: 18847312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.
    Camacho LA; de Aguiar SG; Freire Mda S; Leal Mda L; do Nascimento JP; Iguchi T; Lozana JA; Farias RH;
    Rev Saude Publica; 2005 Jun; 39(3):413-20. PubMed ID: 15997317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
    Valim V; Machado KLLL; Miyamoto ST; Pinto AD; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Dias JGF; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; da Costa-Rocha IA; de Lima SMB; Miranda EH; Trindade GF; Maia MLS; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Casagrande TZ; Oliveira KG; Moura BCDM; Nicole-Batista F; Rodrigues LC; Clemente TB; Magalhães ES; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Costa CZ; Giovelli RA; Brandão LR; Polito ETL; Koehlert IO; Borjaille BP; Pereira DB; Dias LH; Merlo DL; Genelhu LFF; Pretti FZ; Giacomin MDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Martins-Filho OA
    Front Immunol; 2020; 11():1382. PubMed ID: 32765496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.
    Farez MF; Correale J
    Arch Neurol; 2011 Oct; 68(10):1267-71. PubMed ID: 21670384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.
    Veit O; Niedrig M; Chapuis-Taillard C; Cavassini M; Mossdorf E; Schmid P; Bae HG; Litzba N; Staub T; Hatz C; Furrer H;
    Clin Infect Dis; 2009 Mar; 48(5):659-66. PubMed ID: 19191654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The yellow fever 17D virus as a platform for new live attenuated vaccines.
    Bonaldo MC; Sequeira PC; Galler R
    Hum Vaccin Immunother; 2014; 10(5):1256-65. PubMed ID: 24553128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa.
    Jia Q; Jia C; Liu Y; Yang Y; Qi J; Tong L; Chen H; Zhang M; Che J; Li B; Li Z
    Antiviral Res; 2019 Feb; 162():1-4. PubMed ID: 30529359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.
    Barrett AD; Monath TP; Barban V; Niedrig M; Teuwen DE
    Vaccine; 2007 Apr; 25(15):2758-65. PubMed ID: 17368349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Yellow fever vaccine for patients with HIV infection.
    Barte H; Horvath TH; Rutherford GW
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD010929. PubMed ID: 24453061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study.
    Azevedo LS; Lasmar EP; Contieri FL; Boin I; Percegona L; Saber LT; Selistre LS; Netto MV; Moreira MC; Carvalho RM; Bruno RM; Ferreira TC; David-Neto E
    Transpl Infect Dis; 2012 Jun; 14(3):237-41. PubMed ID: 22093046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.
    Pfister M; Kürsteiner O; Hilfiker H; Favre D; Durrer P; Ennaji A; L'Age-Stehr J; Kaufhold A; Herzog C
    Am J Trop Med Hyg; 2005 Mar; 72(3):339-46. PubMed ID: 15772332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization of the 17D-204 yellow fever vaccine.
    Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F
    Vaccine; 2015 Oct; 33(41):5432-5436. PubMed ID: 26314624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas].
    Dabrowska MM; Flisiak R
    Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
    Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
    Front Immunol; 2020; 11():577751. PubMed ID: 33133096
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.
    Roukens AH; Soonawala D; Joosten SA; de Visser AW; Jiang X; Dirksen K; de Gruijter M; van Dissel JT; Bredenbeek PJ; Visser LG
    PLoS One; 2011; 6(12):e27753. PubMed ID: 22163273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease.
    Barrett ADT
    Vaccine; 2017 Oct; 35(44):5951-5955. PubMed ID: 28366605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.